Ticker Symbol: APLS
Apellis Pharmaceuticals Inc
$47.11 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001492422
Company Profile
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 100 5th Avenue
Website: http://apellis.com/
CEO: Cedric Francois
Tags:
- Distribution Services
- Medical Distributors
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $46.40
Change:
$0.22
(
0.48%)
Days Range: $46.07 - $47.97
Beta: 0.65
52wk. High: $94.75
52wk. Low: $19.82
Ytd. Change -9.79%
50 Day Moving Average: $43.36
200 Day Moving Average: $62.42
Shares Outstanding: 117737289
Valuation
Market Cap: 546.3B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A